Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Trial Profile

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Nimodipine (Primary) ; Nimodipine
  • Indications Cerebral ischaemia; Subarachnoid haemorrhage
  • Focus Registrational; Therapeutic Use
  • Acronyms NEWTON 2
  • Sponsors Edge Therapeutics
  • Most Recent Events

    • 01 Aug 2017 According to an Edge Therapeutics media release, the company look forward to the pre-planned futility analysis in late 2017, top-line efficacy interim analysis results in the first quarter of 2018 and top-line results from the full study in late 2018.
    • 03 May 2017 According to an Edge Therapeutics media release, the company has activated the first clinical site in Europe in this trial.
    • 17 Feb 2017 According to the Edge Therapeutics media release, data will be presented at the International Stroke Conference (ISC) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top